Roche temporarily halted recruiting patients to the company’ s Phase II MODUL clinical trial for metastatic colorectal cancer after four patient deaths.
Deal activity is rampant as Big Pharma gobbles up next-generation medicines and technologies to help overcome maturing pipelines and biosimilar threats.
For the pharmaceutical industry, 2016 brought new blockbusters onto the market to ease the pain of patent expirations.
vTv Therapeutics’ azeliragon failed to meet either co-primary efficacy endpoint in the Phase III STEADFAST clinical trial. The new drug candidate was being evaluated in patients with mild Alzheimer’s disease.
Alzheimer’s researchers proposed a radical change in the way the disease is defined, focusing on biological changes in the body rather than clinical symptoms such as memory loss and cognitive decline.
Menlo Therapeutics’ stock dropped 55 percent in premarket trading after the company’s serlopitant failed to meet primary and secondary endpoints in a Phase II clinical trial.
AbbVie announced positive top-line data from the company’s Phase III SELECT-COMPARE clinical trial of upadacitinib in moderate-to-severe rheumatoid arthritis.
Israel’s Therapix Biosciences announced positive results from a Phase IIa trial of its cannabinoid-based drug to treat Tourette syndrome (TS), sending the company’s stock price jumping.
Merck & Co.’s blockbuster drug Keytruda helped previously untreated lung cancer patients live longer in a late-stage trial.
An independent committee concluded that Inctye Corp.’s drug for a type of skin cancer in combination with Merck & Co.’s Keytruda failed to meet the main goal in a late-stage study.
An experimental smartphone application could monitor changes in Parkinson’s disease symptoms throughout the day, sending data to doctors to help them treat patients, U.S. researchers say.
Eli Lilly and Co.’s cancer drug Cyramza helped patients with liver cancer live longer, meeting the main goal of a late-stage trial four years after failing a prior study.
An experimental smartphone app might be an effective alternative to a traditional method of assessing circulation in people who need surgery to restore normal blood flow to the heart, a small study suggests.
As Rigel Pharmaceuticals awaits a regulatory decision for Tavalisse (fostamatinib) for a platelet disorder, the company reported a developmental setback for the therapy in another clinical trial.
A research group at Yale University and from Hanyang University, South Korea, developed a new RNA therapy for West Nile Virus.
Pfizer Inc.’s experimental drug to treat a rare and fatal disease linked to heart failure reduced deaths and need for hospitalizations in a late-stage study.
La Jolla, Calif.-based MediciNova announced that the company’s Phase II clinical trial of ibudilast (MN-166) failed to meet its primary endpoint for methamphetamine dependence.
Shares of AnaptysBio climbed after the company released positive interim data for its experimental peanut allergy treatment.
An ischemic stroke occurs as a result of an obstruction within a blood vessel supplying blood to the brain and accounts for about 87 percent of all strokes, according to the American Stroke Association. A common treatment used to break up the clots and prevent brain damage has become mired in controversy.
Esperion Therapeutics’ experimental oral drug met the main goal of reducing cholesterol by 30 percent in patients who were already on another treatment to lower the risk of artery-clogging heart disease.
Ablynx’s anti-IL-6R nanobody vobarilizumab did not meet primary endpoints in a Phase II dosing study for lupus patients.
ImmunoGen released positive efficacy and tolerability data from its FORWARD II trial of mirvetuximab soravtansine in combination with Merck’s Keytruda in platinum-resistant epithelial ovarian cancer.